fbpx
Wikipedia

Norman Sharpless

February 18, 2023

Norman Edward "Ned" Sharpless (born September 20, 1966) is the previous Director of the National Cancer Institute (NCI). Before that, Sharpless was Professor of Medicine and Genetics Chair, Director of University of North Carolina UNC Lineberger Comprehensive Cancer Center, Molecular Therapeutics, Wellcome Distinguished Professorship in Cancer Research.[1]

Norman Sharpless
15th Director of the National Cancer Institute
In office
October 17, 2017 (2017-10-17) – April 30, 2022 (2022-04-30)
PresidentDonald Trump
Joe Biden
Preceded byHarold E. Varmus
Douglas R. Lowy (acting)
Succeeded byMonica Bertagnolli
Acting Commissioner of Food and Drugs
In office
April 5, 2019 (2019-04-05) – November 1, 2019 (2019-11-01)
PresidentDonald Trump
SecretaryAlex Azar
Preceded byScott Gottlieb
Succeeded byBrett Giroir (acting)
Personal details
Born (1966-09-20) September 20, 1966 (age 56)
Greensboro, North Carolina
NationalityAmerican
Alma mater
Known forp16LUC model
Scientific career
FieldsMolecular genetics
Institutions

Sharpless was named to head the NCI on June 10, 2017,[2] and took office on October 17, 2017. Sharpless also served as Acting Commissioner of the Food and Drugs from April 5, 2019[3][4] until November 1, 2019, after which he returned to the NCI.[5] He stepped down from the post at the end of April 2022.[6][7]

Education

Sharpless studied mathematics at the University of North Carolina at Chapel Hill, where he was a John Motley Morehead Scholar. He earned his medical degree with honors and distinction at the University of North Carolina School of Medicine. He completed his internship and residency at Massachusetts General Hospital in Boston, and a clinical and research fellowship at Dana–Farber Cancer Institute in Boston.[8]

Career

 
Sharpless, as acting Commissioner of Food and Drugs, in the Oval Office with President Donald Trump in 2019

At the University of North Carolina at Chapel Hill, Sharpless ran a basic science laboratory that utilized genetically engineered mice to study cancer and aging, and was co-founder and co-director of the UNC Lineberger Mouse Phase I Unit. His research focused on how normal cells age and undergo malignant conversion.[1]

In 2009, Sharpless's lab identified p16INK4a expression in human peripheral blood T-lymphocytes as an easily measurable biomarker of human molecular age and developed a clinically applicable assay for potential personalized patient risk assessment,[9][10] which was featured on BBC News and other international news agencies for its promise to eventually “measure” human aging.[11] The biomarker was subsequently shown to be a clinical outcome predictor in kidney transplant.[12][13][14] The biomarker assay was commercialized by a clinical-phase biotech company called Sapere Bio (formerly HealthSpan Dx), founded by Sharpless and his team.[15]

He has published numerous papers that show the role of p16INK4a in shutting down the stem cells that renew the body's various tissues.[16][17] He is also one of the founders of G1 Therapeutics, listed $GTHX under the NASDAQ, which is a clinical-stage biopharmaceutical company developing small-molecule therapies for the treatment of patients with cancer. Extending upon this work, Sharpless' team developed the p16LUC model, a genetically engineered mouse that 'glows' upon activation of the p16INK4a promoter due to insertion of firefly luciferase in place of the endogenous gene.[18] Use of this system revealed the activation of p16INK4a in tissues surrounding nascent tumors, allowing scientists to non-invasively visualize the formation and progression of spontaneous cancers in living animals. Furthermore, this allele has made it feasible to better understand aging toxicology. Specifically, Ned's lab has used the p16LUC allele to understand how low dose toxic exposure over a lifetime can affect the rate of molecular aging.[19] He is also a founder of Sapere Bio (formerly HealthSpan Diagnostics), a clinical-phase biotechnology company measuring physiologic reserve to improve healthcare.

Most recently, Sharpless with Judith Campisi, PhD, of the Buck Institute for Research on Aging, and colleagues demonstrated In 2016 how chemotherapy triggers cellular senescence, a pro-inflammatory stress response, which promotes the adverse effects of chemotherapy as well as cancer relapse and metastasis. Eliminating the senescent cells in mice prevented the side effects.[20] He has also reported on meta-analyses of GWAS studies of aging and disease, identifying the major histocompatibility complex and the p16INK4a/ARF loci as the most frequently reported disease associated loci in humans[citation needed].

In 2009, Sharpless and his team were the first to discover altered human INK4/ARF expression as the mechanism for the 9p21.3 genetic risk allele of atherosclerosis.[21] This was first published study identifying the underlying mechanism of 9p21.3, a genetic risk variant with the strongest, and most consistent association with atherosclerosis in multiple, independent, large-scale GWASs (Genome Wide Association Studies).[22] The findings remain to be the most plausible mechanism of 9p21.3 atherosclerosis risk up to this date.[22]

In 2011, Sharpless and his team, using conditional p16INK4a knock-out mouse models, discovered that p16INK4a plays lineage-specific roles of tumor suppression or aging promotion in immune system, providing the first genetic evidence for lineage-specific pleiotropy in immune aging and genetic basis for heterogeneity of human aging and cancer susceptibility.[23][24][25]

In 2010 Sharpless's lab reported the first known human circular RNA produced from a long non-coding RNA, and linked its expression to alleles strongly associated with risk of atherosclerosis.[26]

In 2013 Sharpless and his lab cataloged a large list of circular RNAs in human cell lines and mouse tissues using a whole genome sequencing strategy employing RNase R digestion. These were identified as highly stable transcripts, and reported the first link between circular RNAs and ALU Elements. Sharpless coined the term "backsplicing" to refer to the process by which these circular RNAs might be formed.[27]

In August 2013, he was appointed director of UNC Lineberger Comprehensive Cancer Center.[8]

Publications, awards, professional positions and honors

Sharpless has authored or co-authored more than 170 original reports, reviews and book chapters recorded in the PubMed.gov database[28] and has served as an editor of Aging Cell and the Journal of Clinical Investigation. He has 12 issued or pending patents for his inventions.[29] Sharpless’ honors include being the 2007 recipient of the Jefferson Pilot Award, the 2009 recipient of the Hettleman Prize for Scholarly Achievement,[30] a 2010 recipient of a Glenn Award for Research in Biological Mechanisms of Aging,[31] and a 2012 “Triangle Business Journal Health Care Hero.”[32] He is an elected member of the American Society of Clinical Investigation (ASCI),[33] the nation's oldest honor society for physician-scientists, and the Association of American Physicians.

In 2016, Sharpless was elected to a three-year term on the Association of American Cancer Institutes’ board of directors.[34] He is an appointed member of the National Institute of Aging’s National Advisory Council on Aging.[35]

Personal life

Sharpless is married with two children. Sharpless' wife, Julie Sharpless, worked as a physician and associate professor at the University of North Carolina. Sharpless currently lives in Washington, D.C.

References

  1. ^ a b . unclineberger.org. Archived from the original on April 14, 2015.
  2. ^ McGinley, Laurie (June 10, 2017). "UNC oncologist and researcher named head of the National Cancer Institute". Washington Post. Retrieved June 10, 2017.
  3. ^ Kaplan, Sheila; Hoffman, Jan (March 5, 2019). "F.D.A. Commissioner Scott Gottlieb, Who Fought Teenage Vaping, Resigns". The New York Times. ISSN 0362-4331. Retrieved May 12, 2022.
  4. ^ Kaplan, Sheila (March 12, 2019). "National Cancer Chief, Ned Sharpless, Named F.D.A.'s Acting Commissioner". The New York Times. ISSN 0362-4331. Retrieved May 12, 2022.
  5. ^ McGinley, Laurie (November 1, 2019). "Trump announces plan to nominate Texas cancer doctor to run FDA". The Washington Post. Retrieved November 2, 2019.{{cite news}}: CS1 maint: url-status (link)
  6. ^ "Norman Sharpless steps down as director of the National Cancer Institute". National Institutes of Health (NIH) (Press release). NCI Press Office. April 4, 2022. Retrieved May 12, 2022.
  7. ^ Kaiser, Jocelyn (April 4, 2022). "Top U.S. cancer institute in line for new leadership as director announces departure". Science. doi:10.1126/science.abq3771. Retrieved May 12, 2022.
  8. ^ a b "Dr. Norman Sharpless appointed director of UNC Lineberger Comprehensive Cancer Center". UNC Health Care. Retrieved March 28, 2017.
  9. ^ Liu, Y.; Sanoff, H. K.; Cho, H.; Burd, C. E.; Torrice, C.; Ibrahim, J.G.; Sharpless, N. E. (2009). "Expression of p16INK4a in peripheral blood T-cells is a biomarker of human aging". Aging Cell. 8 (4): 439–448. doi:10.1111/j.1474-9726.2009.00489.x. PMC 2752333. PMID 19485966.
  10. ^ Tsygankov, D.; Liu, Y.; Sanoff, H. K.; Sharpless, N. E.; Elston, T. C. (2009). "A quantitative model for age-dependent expression of the p16INK4a tumor suppressor". Proceedings of the National Academy of Sciences. 106 (39): 16562–16567. Bibcode:2009PNAS..10616562T. doi:10.1073/pnas.0904405106. PMC 2757807. PMID 19805338.
  11. ^ "Hope for test to measure ageing". June 16, 2009.
  12. ^ Gingell-Littlejohn, M; McGuinness, D; McGlynn, LM; Kingsmore, D; Stevenson, KS; Koppelstaetter, C; et al. (2013). "Pre-Transplant CDKN2A Expression in Kidney Biopsies Predicts Renal Function and Is a Future Component of Donor Scoring Criteria". PLOS ONE. 8 (7): e68133. Bibcode:2013PLoSO...868133G. doi:10.1371/journal.pone.0068133. PMC 3701657. PMID 23861858.
  13. ^ Koppelstaetter, C.; Schratzberger, G.; Perco, P.; et al. (2008). "Markers of cellular senescence in zero hour biopsies predict outcome in renal transplantation". Aging Cell. 7 (4): 491–497. doi:10.1111/j.1474-9726.2008.00398.x. PMID 18462273. S2CID 37151355.
  14. ^ Braun, H; Schmidt, BMW; Raiss, M; et al. (2012). "Cellular Senescence Limits Regenerative Capacity and Allograft Survival". Journal of the American Society of Nephrology. 23 (9): 1467–1473. doi:10.1681/ASN.2011100967. PMC 3431409. PMID 22797186.
  15. ^ "Mon Artisan Direct - Isolation - VMC - Pompe à chaleur - Douche PMR". My Blog (in French). Retrieved May 12, 2022.
  16. ^ "Gene Found to Switch Off Stem Cells During Aging". The New York Times. September 6, 2006. Retrieved September 30, 2015.
  17. ^ Kim, WY; Sharpless, NE (October 20, 2006). "The regulation of INK4/ARF in cancer and aging". Cell. 127 (2): 265–75. doi:10.1016/j.cell.2006.10.003. PMID 17055429. S2CID 18280031.
  18. ^ Burd, Christin E.; Sorrentino, Jessica A.; Clark, Kelly S.; Darr, David B.; Krishnamurthy, Janakiraman; Deal, Allison M.; Bardeesy, Nabeel; Castrillon, Diego H.; Beach, David H. (January 17, 2013). "Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model". Cell. 152 (1–2): 340–351. doi:10.1016/j.cell.2012.12.010. ISSN 1097-4172. PMC 3718011. PMID 23332765.
  19. ^ Sorrentino, J; Krishnamurthy, K; Tilley, S; Alb, JG; Burd, C; Sharpless, N (2014). "p16INK4a reporter mice reveal age-promoting effects of environmental toxicants". Journal of Clinical Investigation. 124 (1): 169–73. doi:10.1172/JCI70960. PMC 3871242. PMID 24334456.
  20. ^ Demaria, Marco; O'Leary, Monique N.; Chang, Jianhui; Shao, Lijian; Liu, Su; Alimirah, Fatouma; Koenig, Kristin; Le, Catherine; Mitin, Natalia (February 1, 2017). "Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse". Cancer Discovery. 7 (2): 165–176. doi:10.1158/2159-8290.CD-16-0241. ISSN 2159-8274. PMC 5296251. PMID 27979832.
  21. ^ Liu, Y; Sanoff, HK; Cho, H; Burd, CE; Torrice, C; Mohlke, KL; et al. (2009). "INK4/ARF Transcript Expression Is Associated with Chromosome 9p21 Variants Linked to Atherosclerosis". PLOS ONE. 4 (4): e5027. Bibcode:2009PLoSO...4.5027L. doi:10.1371/journal.pone.0005027. PMC 2660422. PMID 19343170.
  22. ^ a b Lusis, AJ (2012). "Genetics of Atherosclerosis". Trends in Genetics. 28 (6): 267–275. doi:10.1016/j.tig.2012.03.001. PMC 3362664. PMID 22480919.
  23. ^ Liu, Y.; Johnson, S. M.; Fedoriw, Y.; Rogers, A. B.; Yuan, H.; Krishnamurthy, J.; Sharpless, N. E. (2011). "Expression of p16INK4a prevents cancer and promotes aging in lymphocytes". Blood. 117 (12): 3257–3267. doi:10.1182/blood-2010-09-304402. PMC 3069667. PMID 21245485.
  24. ^ Eshraghi, P.; Rudolph, K. L. (2011). "Lineage-specific pleiotropy in immune aging". Blood. 117 (12): 3250–3251. doi:10.1182/blood-2011-02-332650. PMID 21436077.
  25. ^ Liu, Yan; Sharpless, Norman E (2009). "Tumor suppressor mechanisms in immune aging". Current Opinion in Immunology. 21 (4): 431–439. doi:10.1016/j.coi.2009.05.011. PMC 2725203. PMID 19535234.
  26. ^ Burd, CE; Jeck, WR; Liu, Y; et al. (December 2, 2010). "Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk". PLOS Genetics. 6 (12): e1001233. doi:10.1371/journal.pgen.1001233. PMC 2996334. PMID 21151960.
  27. ^ Jeck, WR; Sorrentino, JA; Wang, K; Slevin, MK; Burd, CE; Liu, J; Marzluff, WF; Sharpless, NE (February 2013). "Circular RNAs are abundant, conserved, and associated with ALU repeats". RNA. 19 (2): 141–57. doi:10.1261/rna.035667.112. PMC 3543092. PMID 23249747.
  28. ^ "Sharpless NE[Author] - Search Results - PubMed". PubMed. Retrieved May 12, 2022.
  29. ^ "Norman E. Sharpless Inventions, Patents and Patent Applications - Justia Patents Search". patents.justia.com. Retrieved March 28, 2017.
  30. ^ Outlaw, Jonathan (August 26, 2009). "Hettleman Prize winners span the arts and sciences". UNC News Archives. Retrieved May 12, 2022.
  31. ^ "Glenn Foundation for Medical Research Glenn Award for Research in Biological Mechanisms of Aging". glennfoundation.org. Retrieved May 12, 2022.
  32. ^ "Winner: Dr. Norman Sharpless – Innovator/Researcher". www.bizjournals.com. Retrieved March 28, 2017.
  33. ^ "The American Society for Clinical Investigation". www.the-asci.org. Retrieved March 28, 2017.
  34. ^ "AACI". www.aaci-cancer.org. Retrieved March 28, 2017.
  35. ^ Aging, National Institute on (September 7, 2011). "NACA Membership Roster". National Institute on Aging. Retrieved March 28, 2017.

External links

  •   Media related to Norman Sharpless at Wikimedia Commons
Government offices
Preceded by 15th Director of the National Cancer Institute
2017 – present 		Incumbent

February 18, 2023
norman, sharpless, norman, edward, sharpless, born, september, 1966, previous, director, national, cancer, institute, before, that, sharpless, professor, medicine, genetics, chair, director, university, north, carolina, lineberger, comprehensive, cancer, cente. Norman Edward Ned Sharpless born September 20 1966 is the previous Director of the National Cancer Institute NCI Before that Sharpless was Professor of Medicine and Genetics Chair Director of University of North Carolina UNC Lineberger Comprehensive Cancer Center Molecular Therapeutics Wellcome Distinguished Professorship in Cancer Research 1 Norman Sharpless15th Director of the National Cancer InstituteIn office October 17 2017 2017 10 17 April 30 2022 2022 04 30 PresidentDonald TrumpJoe BidenPreceded byHarold E VarmusDouglas R Lowy acting Succeeded byMonica BertagnolliActing Commissioner of Food and DrugsIn office April 5 2019 2019 04 05 November 1 2019 2019 11 01 PresidentDonald TrumpSecretaryAlex AzarPreceded byScott GottliebSucceeded byBrett Giroir acting Personal detailsBorn 1966 09 20 September 20 1966 age 56 Greensboro North CarolinaNationalityAmericanAlma materUniversity of North Carolina at Chapel HillUniversity of North Carolina School of MedicineKnown forp16LUC modelScientific careerFieldsMolecular geneticsInstitutionsUniversity of North Carolina at Chapel HillNational Cancer InstituteSharpless was named to head the NCI on June 10 2017 2 and took office on October 17 2017 Sharpless also served as Acting Commissioner of the Food and Drugs from April 5 2019 3 4 until November 1 2019 after which he returned to the NCI 5 He stepped down from the post at the end of April 2022 6 7 Contents 1 Education 2 Career 3 Publications awards professional positions and honors 4 Personal life 5 References 6 External linksEducation EditSharpless studied mathematics at the University of North Carolina at Chapel Hill where he was a John Motley Morehead Scholar He earned his medical degree with honors and distinction at the University of North Carolina School of Medicine He completed his internship and residency at Massachusetts General Hospital in Boston and a clinical and research fellowship at Dana Farber Cancer Institute in Boston 8 Career Edit Sharpless as acting Commissioner of Food and Drugs in the Oval Office with President Donald Trump in 2019 At the University of North Carolina at Chapel Hill Sharpless ran a basic science laboratory that utilized genetically engineered mice to study cancer and aging and was co founder and co director of the UNC Lineberger Mouse Phase I Unit His research focused on how normal cells age and undergo malignant conversion 1 In 2009 Sharpless s lab identified p16INK4a expression in human peripheral blood T lymphocytes as an easily measurable biomarker of human molecular age and developed a clinically applicable assay for potential personalized patient risk assessment 9 10 which was featured on BBC News and other international news agencies for its promise to eventually measure human aging 11 The biomarker was subsequently shown to be a clinical outcome predictor in kidney transplant 12 13 14 The biomarker assay was commercialized by a clinical phase biotech company called Sapere Bio formerly HealthSpan Dx founded by Sharpless and his team 15 He has published numerous papers that show the role of p16INK4a in shutting down the stem cells that renew the body s various tissues 16 17 He is also one of the founders of G1 Therapeutics listed GTHX under the NASDAQ which is a clinical stage biopharmaceutical company developing small molecule therapies for the treatment of patients with cancer Extending upon this work Sharpless team developed the p16LUC model a genetically engineered mouse that glows upon activation of the p16INK4a promoter due to insertion of firefly luciferase in place of the endogenous gene 18 Use of this system revealed the activation of p16INK4a in tissues surrounding nascent tumors allowing scientists to non invasively visualize the formation and progression of spontaneous cancers in living animals Furthermore this allele has made it feasible to better understand aging toxicology Specifically Ned s lab has used the p16LUC allele to understand how low dose toxic exposure over a lifetime can affect the rate of molecular aging 19 He is also a founder of Sapere Bio formerly HealthSpan Diagnostics a clinical phase biotechnology company measuring physiologic reserve to improve healthcare Most recently Sharpless with Judith Campisi PhD of the Buck Institute for Research on Aging and colleagues demonstrated In 2016 how chemotherapy triggers cellular senescence a pro inflammatory stress response which promotes the adverse effects of chemotherapy as well as cancer relapse and metastasis Eliminating the senescent cells in mice prevented the side effects 20 He has also reported on meta analyses of GWAS studies of aging and disease identifying the major histocompatibility complex and the p16INK4a ARF loci as the most frequently reported disease associated loci in humans citation needed In 2009 Sharpless and his team were the first to discover altered human INK4 ARF expression as the mechanism for the 9p21 3 genetic risk allele of atherosclerosis 21 This was first published study identifying the underlying mechanism of 9p21 3 a genetic risk variant with the strongest and most consistent association with atherosclerosis in multiple independent large scale GWASs Genome Wide Association Studies 22 The findings remain to be the most plausible mechanism of 9p21 3 atherosclerosis risk up to this date 22 In 2011 Sharpless and his team using conditional p16INK4a knock out mouse models discovered that p16INK4a plays lineage specific roles of tumor suppression or aging promotion in immune system providing the first genetic evidence for lineage specific pleiotropy in immune aging and genetic basis for heterogeneity of human aging and cancer susceptibility 23 24 25 In 2010 Sharpless s lab reported the first known human circular RNA produced from a long non coding RNA and linked its expression to alleles strongly associated with risk of atherosclerosis 26 In 2013 Sharpless and his lab cataloged a large list of circular RNAs in human cell lines and mouse tissues using a whole genome sequencing strategy employing RNase R digestion These were identified as highly stable transcripts and reported the first link between circular RNAs and ALU Elements Sharpless coined the term backsplicing to refer to the process by which these circular RNAs might be formed 27 In August 2013 he was appointed director of UNC Lineberger Comprehensive Cancer Center 8 Publications awards professional positions and honors EditSharpless has authored or co authored more than 170 original reports reviews and book chapters recorded in the PubMed gov database 28 and has served as an editor of Aging Cell and the Journal of Clinical Investigation He has 12 issued or pending patents for his inventions 29 Sharpless honors include being the 2007 recipient of the Jefferson Pilot Award the 2009 recipient of the Hettleman Prize for Scholarly Achievement 30 a 2010 recipient of a Glenn Award for Research in Biological Mechanisms of Aging 31 and a 2012 Triangle Business Journal Health Care Hero 32 He is an elected member of the American Society of Clinical Investigation ASCI 33 the nation s oldest honor society for physician scientists and the Association of American Physicians In 2016 Sharpless was elected to a three year term on the Association of American Cancer Institutes board of directors 34 He is an appointed member of the National Institute of Aging s National Advisory Council on Aging 35 Personal life EditSharpless is married with two children Sharpless wife Julie Sharpless worked as a physician and associate professor at the University of North Carolina Sharpless currently lives in Washington D C References Edit a b Norman E Sharpless UNC Lineberger Comprehensive Cancer Center unclineberger org Archived from the original on April 14 2015 McGinley Laurie June 10 2017 UNC oncologist and researcher named head of the National Cancer Institute Washington Post Retrieved June 10 2017 Kaplan Sheila Hoffman Jan March 5 2019 F D A Commissioner Scott Gottlieb Who Fought Teenage Vaping Resigns The New York Times ISSN 0362 4331 Retrieved May 12 2022 Kaplan Sheila March 12 2019 National Cancer Chief Ned Sharpless Named F D A s Acting Commissioner The New York Times ISSN 0362 4331 Retrieved May 12 2022 McGinley Laurie November 1 2019 Trump announces plan to nominate Texas cancer doctor to run FDA The Washington Post Retrieved November 2 2019 a href Template Cite news html title Template Cite news cite news a CS1 maint url status link Norman Sharpless steps down as director of the National Cancer Institute National Institutes of Health NIH Press release NCI Press Office April 4 2022 Retrieved May 12 2022 Kaiser Jocelyn April 4 2022 Top U S cancer institute in line for new leadership as director announces departure Science doi 10 1126 science abq3771 Retrieved May 12 2022 a b Dr Norman Sharpless appointed director of UNC Lineberger Comprehensive Cancer Center UNC Health Care Retrieved March 28 2017 Liu Y Sanoff H K Cho H Burd C E Torrice C Ibrahim J G Sharpless N E 2009 Expression of p16INK4a in peripheral blood T cells is a biomarker of human aging Aging Cell 8 4 439 448 doi 10 1111 j 1474 9726 2009 00489 x PMC 2752333 PMID 19485966 Tsygankov D Liu Y Sanoff H K Sharpless N E Elston T C 2009 A quantitative model for age dependent expression of the p16INK4a tumor suppressor Proceedings of the National Academy of Sciences 106 39 16562 16567 Bibcode 2009PNAS 10616562T doi 10 1073 pnas 0904405106 PMC 2757807 PMID 19805338 Hope for test to measure ageing June 16 2009 Gingell Littlejohn M McGuinness D McGlynn LM Kingsmore D Stevenson KS Koppelstaetter C et al 2013 Pre Transplant CDKN2A Expression in Kidney Biopsies Predicts Renal Function and Is a Future Component of Donor Scoring Criteria PLOS ONE 8 7 e68133 Bibcode 2013PLoSO 868133G doi 10 1371 journal pone 0068133 PMC 3701657 PMID 23861858 Koppelstaetter C Schratzberger G Perco P et al 2008 Markers of cellular senescence in zero hour biopsies predict outcome in renal transplantation Aging Cell 7 4 491 497 doi 10 1111 j 1474 9726 2008 00398 x PMID 18462273 S2CID 37151355 Braun H Schmidt BMW Raiss M et al 2012 Cellular Senescence Limits Regenerative Capacity and Allograft Survival Journal of the American Society of Nephrology 23 9 1467 1473 doi 10 1681 ASN 2011100967 PMC 3431409 PMID 22797186 Mon Artisan Direct Isolation VMC Pompe a chaleur Douche PMR My Blog in French Retrieved May 12 2022 Gene Found to Switch Off Stem Cells During Aging The New York Times September 6 2006 Retrieved September 30 2015 Kim WY Sharpless NE October 20 2006 The regulation of INK4 ARF in cancer and aging Cell 127 2 265 75 doi 10 1016 j cell 2006 10 003 PMID 17055429 S2CID 18280031 Burd Christin E Sorrentino Jessica A Clark Kelly S Darr David B Krishnamurthy Janakiraman Deal Allison M Bardeesy Nabeel Castrillon Diego H Beach David H January 17 2013 Monitoring tumorigenesis and senescence in vivo with a p16 INK4a luciferase model Cell 152 1 2 340 351 doi 10 1016 j cell 2012 12 010 ISSN 1097 4172 PMC 3718011 PMID 23332765 Sorrentino J Krishnamurthy K Tilley S Alb JG Burd C Sharpless N 2014 p16INK4a reporter mice reveal age promoting effects of environmental toxicants Journal of Clinical Investigation 124 1 169 73 doi 10 1172 JCI70960 PMC 3871242 PMID 24334456 Demaria Marco O Leary Monique N Chang Jianhui Shao Lijian Liu Su Alimirah Fatouma Koenig Kristin Le Catherine Mitin Natalia February 1 2017 Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse Cancer Discovery 7 2 165 176 doi 10 1158 2159 8290 CD 16 0241 ISSN 2159 8274 PMC 5296251 PMID 27979832 Liu Y Sanoff HK Cho H Burd CE Torrice C Mohlke KL et al 2009 INK4 ARF Transcript Expression Is Associated with Chromosome 9p21 Variants Linked to Atherosclerosis PLOS ONE 4 4 e5027 Bibcode 2009PLoSO 4 5027L doi 10 1371 journal pone 0005027 PMC 2660422 PMID 19343170 a b Lusis AJ 2012 Genetics of Atherosclerosis Trends in Genetics 28 6 267 275 doi 10 1016 j tig 2012 03 001 PMC 3362664 PMID 22480919 Liu Y Johnson S M Fedoriw Y Rogers A B Yuan H Krishnamurthy J Sharpless N E 2011 Expression of p16INK4a prevents cancer and promotes aging in lymphocytes Blood 117 12 3257 3267 doi 10 1182 blood 2010 09 304402 PMC 3069667 PMID 21245485 Eshraghi P Rudolph K L 2011 Lineage specific pleiotropy in immune aging Blood 117 12 3250 3251 doi 10 1182 blood 2011 02 332650 PMID 21436077 Liu Yan Sharpless Norman E 2009 Tumor suppressor mechanisms in immune aging Current Opinion in Immunology 21 4 431 439 doi 10 1016 j coi 2009 05 011 PMC 2725203 PMID 19535234 Burd CE Jeck WR Liu Y et al December 2 2010 Expression of linear and novel circular forms of an INK4 ARF associated non coding RNA correlates with atherosclerosis risk PLOS Genetics 6 12 e1001233 doi 10 1371 journal pgen 1001233 PMC 2996334 PMID 21151960 Jeck WR Sorrentino JA Wang K Slevin MK Burd CE Liu J Marzluff WF Sharpless NE February 2013 Circular RNAs are abundant conserved and associated with ALU repeats RNA 19 2 141 57 doi 10 1261 rna 035667 112 PMC 3543092 PMID 23249747 Sharpless NE Author Search Results PubMed PubMed Retrieved May 12 2022 Norman E Sharpless Inventions Patents and Patent Applications Justia Patents Search patents justia com Retrieved March 28 2017 Outlaw Jonathan August 26 2009 Hettleman Prize winners span the arts and sciences UNC News Archives Retrieved May 12 2022 Glenn Foundation for Medical Research Glenn Award for Research in Biological Mechanisms of Aging glennfoundation org Retrieved May 12 2022 Winner Dr Norman Sharpless Innovator Researcher www bizjournals com Retrieved March 28 2017 The American Society for Clinical Investigation www the asci org Retrieved March 28 2017 AACI www aaci cancer org Retrieved March 28 2017 Aging National Institute on September 7 2011 NACA Membership Roster National Institute on Aging Retrieved March 28 2017 External links Edit Media related to Norman Sharpless at Wikimedia CommonsGovernment officesPreceded byHarold E VarmusDouglas R Lowy acting 15th Director of the National Cancer Institute2017 present Incumbent Retrieved from https en wikipedia org w index php title Norman Sharpless amp oldid 1128240016, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.